{
    "nct_id": "NCT04167514",
    "official_title": "A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant (BMT CTN 1705)",
    "inclusion_criteria": "* Patients 12 years of age or older\n* Initial presentation of acute GVHD after allogeneic hematopoietic cell transplantation for any indication\n* Any graft or donor source or conditioning intensity\n* Clinical diagnosis of acute GVHD requiring systemic therapy with corticosteroids\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Prior exogenous AAT exposure for GVHD prophylaxis\n* Relapsed, progressing, or persistent malignancy\n* de novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment\n* Receiving other drugs for the treatment of GVHD\n* Receiving systemic CS for any indication within 7 days before the onset of acute GVHD",
    "miscellaneous_criteria": ""
}